Procore signs multi-year strategic collaboration agreement with AWS
LONDON - Alliance Pharma (LON:ALAPH) plc has disclosed that one of its directors, Richard McKenzie, intends to acquire 23,000 shares of the company, representing a 0.004% stake, on or after April 24, 2025. This move comes following the announcement on January 10, 2025, of a recommended acquisition of Alliance by Aegros Bidco Limited, a company to be indirectly owned by affiliates of DBAY Advisors Limited and the ERES IV Fund.
The acquisition, which is proposed to be executed through a Court-sanctioned scheme of arrangement, was detailed in a circular on January 31, 2025, and later updated with a final increased cash offer on March 10, 2025. McKenzie’s planned share purchase is a precursor to electing the Alternative Offer, which would allow him to maintain an interest in Alliance as a private company and potentially partake in future value creation, though this outcome is not guaranteed.
The director’s acquisition plan provides at least 24 hours of public notice in compliance with Rule 4.2 of the Takeover Code. However, Alliance’s board cannot advise on the fairness of the Alternative Offer and has not recommended any action to shareholders regarding this option. Shareholders are urged to consider the advantages, disadvantages, and risk factors associated with the Alternative Offer as outlined in the Scheme Document.
This announcement is based on a press release statement, which serves as the source of this information.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.